In comparison to SKI-73 (6a), the CARM1 inhibitors EZM2302 and TP-064 demonstrated anti-proliferation effects on hematopoietic cancer cells, in particular multiple myeloma (Drew et al., 2017; Greenblatt et al., 2018; Nakayama et al., 2018). This evidence concerns the gene CARM1 and cancer.